- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LOTUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STADA ARZNEIMITTEL | - | - | Canson Capital Partners agiert als Federführender Finanzberater von Capvest bei der Akquisition von Stada und co-investiert über seinen Merchant Banking Arm | London (ots/PRNewswire) - STADA ist die sechste Private-Equity-Transaktion, bei der Canson als Finanzberater und Co-Investor auftrittCanson Capital Partners ("Canson") freut sich bekannt zu geben, dass... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 69,82 | +2,44 % | With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis | ||
| CSPC PHARMA | 0,866 | +3,44 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG (SYH2061 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE ... | ||
| SELLAS LIFE SCIENCES | 1,274 | -5,63 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 20,380 | -1,78 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
UBS Global Healthcare Conference
Fireside Chat: Monday, November 10... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,470 | +0,29 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500 | ||
| MADRIGAL PHARMACEUTICALS | 507,60 | -0,51 % | Madrigal Pharmaceuticals: Aktie erreicht Rekordhoch von 578,8 US-Dollar | ||
| METRIOPHARM | - | - | MetrioPharm gains orphan drug status from EMA for MP1032 | ||
| ENZON PHARMACEUTICALS | 0,029 | -32,14 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Announce Amendment to Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| OPUS GENETICS | 1,690 | -2,65 % | Piper Sandler startet Coverage für Opus Genetics mit "Overweight" und 250 % Kurspotenzial | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,440 | +0,45 % | Savara Inc.: Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 | - The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% - - Changes in DLco%, the Primary Endpoint in IMPALA-2, Were... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,090 | 0,00 % | NSE - Viracta Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| GALECTIN THERAPEUTICS | 4,700 | -8,74 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update | NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 4,000 | -7,41 % | Biodexa Pharmaceuticals PLC: Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP | November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany... ► Artikel lesen |
LOTUS PHARMACEUTICALS INC gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOTUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.